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Abstract
Background—High cholesterol often precedes cardiovascular disease (CVD) and guidelines 
recommend cholesterol screening among at-risk women. Definitions of CVD risk vary and 
prevalence of dyslipidemia (abnormal total cholesterol, high-density lipoprotein (HDL-C), or non-
HDL-C) among at-risk women may vary by age and definition of CVD risk.
Methods—This study used 2007–2008 National Health and Nutrition Examination Survey data 
(n=1,781), a representative sample of the U.S. civilian, non-institutionalized population, to 
estimate the proportion of women without previous dyslipidemia diagnosis who are U.S. 
Preventive Services Task Force (USPSTF) at-risk and American Heart Association (AHA) at-risk. 
We also report dyslipidemia prevalence stratified by age.
Results—Over half (55.0%) of younger women (20–44 years) and 74.2% of older women (≥45 
years) were USPSTF at-risk, while nearly all younger and older women had at least one AHA risk 
factor (99.5% and 99.6%, respectively). Dyslipidemia prevalence among younger women was 
47.3% (95% confidence interval [CI]: 42.2– 52.5) for USPSTF-at-risk and 39.5% (95% CI: 35.7–
43.4) for AHA at-risk. Among older women, it was 65.5% (95% CI: 60.8–69.9) for USPSTF at-
risk and 63.3% (95% CI: 59.0–67.4) for AHA at-risk.
Conclusions—The AHA risk definition identified 45% more young women and 25% more 
older women than the USPSTF risk definition; however, both definitions of at-risk identified 
similar prevalence estimates of dyslipidemia among women. Given a high prevalence of 
dyslipidemia among younger women, future research is needed to assess whether identification 
and treatment of young women with dyslipidemia will decrease CVD mortality among them later 
in life.
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Cardiovascular disease (CVD) is the leading cause of death among women of all ages1 and 
the third leading cause of death among women aged 18–44 years.2 High cholesterol is a 
modifiable risk factor that often precedes heart disease. It also has reproductive health 
significance, as it has been associated with polycystic ovarian syndrome, the most common 
endocrine disorder inwomen of reproductive age and leading cause of infertility.3,4 
Cholesterol screening is the gateway to early detection and control of dyslipidemia. 
Dyslipidemia, a treatable condition characterized by abnormal total cholesterol, high- or 
low-density lipoproteins, is associated with atherogenesis. Cholesterol management is also a 
key strategy of the Healthy People 2020 and Department of Health and Human Services 
(DHHS) “Million Hearts” initiative.5,6
Most national guidelines recommend cholesterol screening for older (≥ 45 years) and 
reproductive age women (20–44 years) based on CVD risk. Definitions of increased CVD 
risk vary across guidelines7–10 and the United States Preventive Services Task Force 
(USPSTF) makes no definitive recommendations for women 20 years or older without 
diabetes, previous personal history of coronary heart disease (CHD) or non-coronary 
atherosclerosis, premature family history of CVD, tobacco use, hypertension (HTN), and 
obesity (≥30 kg/ m2).10 Alternatively, the American Heart Association (AHA) Guidelines 
for CVD prevention in women recognizes a broader array of risk factors that, in addition to 
the USPSTF risk factors, include Framingham 10-year predicted CVD risk ≥ 10%, poor diet, 
physical inactivity, stroke, pre-hypertension, central adiposity, and conditions that are 
unique to or more prevalent among women.7
The rationale for risk-dependent cholesterol screening among women is that the few primary 
prevention lipid trials that enrolled women or those with lower CVD risk were not 
sufficiently powered to demonstrate significant reductions in the risk of coronary 
events.11,12 Given different definitions of CVD risk, it is possible that a broader definition of 
CVD risk would identify more undiagnosed dyslipidemia. The purpose of this study was to 
estimate the prevalence of dyslipidemia among women of reproductive age and among 
women 45 years or older according to the USPSTF and AHA definitions of CVD risk.
Materials and Methods
Sample
Data were drawn from the National Health and Nutrition Examination Survey (NHANES), a 
representative sample of the U.S. civilian, non-institutionalized population.13 Detailed 
descriptions of NHANES are available on the National Center for Health Statistics 
website.13 Briefly, NHANES uses a complex, multistage, probability design and begins with 
in home personal interviewing. Next, physical examinations, lab tests, and additional 
questionnaires are administered in specially designed and equipped mobile examination 
centers. The overall response rate for completed examinations among all screened female 
participants was 75.5% (2007–2008).
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Women age ≥ 20 years who reported no past diagnosis of high cholesterol were included (n 
= 2037). Women with missing data on non-fasting cholesterol measures and at-risk variables 
included in USPSTF and AHA criteria (n = 256, 12.6%)7,8 were excluded, leaving a final 
analytic sample of n = 1,781. Data were de-identified and publically available; therefore, 
this research did not involve human subjects and was exempt from institutional review board 
review.
Definitions and measurement
Binary variables were created to connote CVD risk status that included risk factors for 
which data was available in NHANES, 2007–2008 (Table 1). USPSTF-at-risk was defined 
as presence of ≥ 1 of the following risk factors: CHD (ever being told by a doctor or other 
health professional that they have congestive heart failure, coronary heart disease, angina, or 
myocardial infarction), diabetes (ever told they had diabetes or current hemoglobin A1c 
measurement ≥6.5%), hypertension (self-reported current use of antihypertensive 
medication or average of ≤3 blood pressure [BP] measurements ≥140/90 mmHg), tobacco 
use (self-reported currently smoking every day or some days and ever smoking ≥100 
cigarettes), obesity (body mass index: weight [kilograms]/ height [meters2] ≥30),10 and 
family history of CVD (heart attack or angina before age 50 in a close biological relative). 
AHA-at-risk was defined as ≥ 1 USPSTF risk factors or stroke (ever told they had a stroke), 
chronic kidney disease (self-reported physician diagnosis of weak or failing kidneys or 
diminished kidney function based on the glomerular filtration rate),14 pre-hypertension 
(average of ≤3BP measurements 120–139/80–89 mmHg), central adiposity (waist 
circumference > 88 centimeters), poor diet (Table 2: self-reported mean intake of < 3 
selected Dietary Approaches to Stop Hypertension [DASH]15 or AHA7 recommended 
targets according to the average of two 24-hour recall interviews—if dietary information 
was missing for one day only the single completed dietary recall was used), physical 
inactivity (self-reported < 150 minutes of moderate- or < 75 minutes of vigorous-effort 
leisure time activity in a typical week, or an equivalent combination), gestational diabetes 
mellitus history (ever told they had diabetes during pregnancy but had not been diagnosed 
with diabetes other than during pregnancy), rheumatoid arthritis (ever told they had this 
condition), and Framingham 10-year CHD risk ≥ 10% (Table 1, details on the calculation of 
Framingham scores and 10-year risk estimates available at: www.nhlbi.nih.gov/guidelines/
cholesterol8). The data did not include measures of gestational hypertension or other 
systemic autoimmune collagen-vascular disease like lupus, which are also identified as risk 
factors in AHA guidelines.
Four binary (yes/no) measures of dyslipidemia were created based on non-fasting, lab 
results: high total cholesterol (TC), low high-density lipoprotein cholesterol (HDL-C), high 
non-HDL-C (surrogate for low-density lipoprotein cholesterol [LDL-C]), and any 
dyslipidemia. The University of Minnesota performed the testing using Roche Modular P 
chemistry analyzer equipment (Roche Diagnostics) as described elsewhere.16 High TC was 
defined as ≥ 200 mg/dL. Low HDL-C was defined as <40 mg/dL. Because LDL-C tests 
require fasting and LDL-C was only collected on a sub-sample, non-HDL-C was used. 
Established thresholds for high LDL-C in the National Cholesterol Education Program Adult 
Treatment Panel (NCEP ATP III) are risk-based (defined below) and include high risk (≥ 
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100 mg/dL), intermediate (≥ 130 mg/dL), and low (≥ 160 mg/dL).8 It is generally accepted 
that a reasonable goal for non-HDL cholesterol is 30 mg/dL higher than the LDL-cholesterol 
threshold.8 Therefore, 30 mg/dL was added to each established risk group threshold to 
estimate high non-HDL-C. Briefly, high non-HDL-C was defined as ≥ 130 mg/dL among 
the high risk group, which included women with coronary heart disease (CHD) or CHD-
equivalent conditions (congestive heart failure, angina, myocardial infarction, stroke, and 
diabetes) and those with ≥2 major CHD risk factors (cigarette smoking, hypertension or 
taking anti-hypertensive medication, age ≥ 55 years, family history of premature CHD, and 
HDL-C <40 mg/dL) and >20% Framingham 10-year CHD risk estimates. Non-HDL-C ≥ 
160 mg/dL was coded as high among the intermediate risk group, which included women 
who had ≥2 major CHD risk factors and ≤20% Framingham 10-year CHD risk estimates. 
Non-HDL-C ≥ 190 mg/dL was coded as high among the low risk group of women who had 
0–1 major CHD risk factors. Any dyslipidemia was defined as high TC, low HDL-C or high 
non-HDL-C.
Sociodemographic characteristics included age (20–44 years, ≥45 years), race/ethnicity 
(Mexican American, white non-Hispanic, black non-Hispanic, other/multiracial) education 
(< 12th grade, 12th grade/GED/ or high school graduate, some college or associates degree, 
≥ college graduate) and annual family income (0–$24,999, $25,000–$44,999, $45,000– 
$74,999, ≥ $75,000, unknown). Health care access indicators were based on self-report and 
included health insurance (uninsured or private single service plan only, public, private), and 
time since last visit with a health care provider (≤ 12 months, >1 year and ≤3 years, >3 
years, or never).
Data analysis
Data analyses were conducted in 2012 using Stata software (version 11; StataCorp) and 
examination weights, which adjust for unequal probability of selection, interview, and 
examination non-response and non-coverage. These data are representative of the US female 
population aged ≥20 years for 2007–2008 who were not previously diagnosed with high 
cholesterol. The prevalence of sociodemographic characteristics, health care access 
indicators, CVD risk factors, and at-risk women according to USPSTF and AHA definitions 
of CVD risk were estimated and stratified by age (20–44 years versus ≥ 45 years), since the 
risk of developing dyslipidemia increases with age. Differences in distributions of CVD risk 
factors by age were assessed using Pearson chi square tests (p < 0.05) with Rao and Scott 
second-order corrections.17 The prevalence of dyslipidemia (high TC, low HDL-C, high 
non-HDL-C, and any dyslipidemia) was calculated by risk category (USPSTF-at-risk versus 
AHA-at-risk) and stratified by risk and age category. Dyslipidemia prevalence and case to 
screening ratio were estimated by dyslipidemia type among women at-risk according to 
AHA guidelines but not at-risk according to USPSTF guidelines.
Results
Table 3 displays the sociodemographic characteristics, health care access indicators, and 
CVD risk factors for a national sample of women not previously diagnosed with high 
cholesterol by age: reproductive (20–44 years), older (≥ 45 years), and all women age ≥20 
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years. Approximately half of the women in this sample were reproductive age (51.2%); most 
were non-Hispanic white (68.0%), and had at least some college education (57.4%). A larger 
percentage of reproductive age women reported incomes $45,000–$74,000 (25.0%) 
compared with older women (18.5%). The vast majority (96.8%) had seen a health care 
provider within the previous three years and 62.1% reported receipt of a cholesterol test 
within the previous five years. Among all women, 34.2% were obese, 90.8% had an 
unhealthy diet, and 68.1% were insufficiently active or inactive. Rheumatoid arthritis was 
reported by 4.0% of the sample and 5.2% reported having a history of gestational diabetes. 
The prevalence of CVD risk factors was generally higher among older women with the 
exceptions of current smoking and unhealthy diet, which were higher among reproductive 
age women (p < 0.05). Over half of reproductive age women (55.0%) and 74.2% of older 
women were USPSTF-at-risk. Nearly all reproductive age and older women were AHA-at-
risk (99.5% and 99.6%, respectively).
Among USPSTF-at-risk, reproductive age women, nearly half (47.3%) had some form of 
dyslipidemia, one-third (33.0%) had high TC, 20.7% had low HDL-C, and 13.1% had high 
non-HDL-C (Table 4). Among older, USPSTF-at-risk women, 65.5% had dyslipidemia, 
54.5% had high TC, 12.5% had low HDL-C, and 36.2% had high non-HDL-C (Table 4). 
Prevalence estimates of non-HDL-C for reproductive age and older women alike were 
consistently lower using AHA criteria (8.0% and 28.3%, respectively) than with the 
USPSTF criteria (13.1% and 36.2%, respectively), and the same pattern held for other types 
of dyslipidemia, although confidence intervals overlapped. Of women identified as AHA-at-
risk but not USPSTF-at-risk, 38.3% had dyslipidemia. Among AHA-at-risk only women 
(i.e., currently not eligible for USPSTF-risk based cholesterol screening), 1 in 35 have high 
non-HDL-C warranting lifestyle modification or pharmacologic management. The majority 
of women who were AHA-at-risk only were reproductive age (69.0%), physically inactive 
(57.6%), or had an unhealthy diet (92.1%; not shown).
Discussion
Nearly all reproductive age and older women had at least one CVD risk factor according to 
AHA guidelines (99.5% and 99.6%, respectively).7 This is not surprising as others have 
reported only 1% of the U.S. population has ideal cardiovascular health.18,19 Unhealthy diet 
was prevalent among younger (93%) and older (88%) women alike. A high prevalence 
(38%) of dyslipidemia was reported among AHA-at-risk women. These women (estimated 
>25 million) had no previous personal history of high cholesterol, diabetes, CHD or non-
coronary atherosclerosis, premature family history of CVD, or current tobacco use, 
hypertension (HTN), or obesity (≥30kg/m2). This represents nearly 10 million additional 
new cases of any dyslipidemia and over 715,000 cases of high non-HDL-C (a proxy for 
LDL-C—the primary target of pharmacologic treatment).
High prevalence of dyslipidemia was reported among reproductive age women (40%, AHA-
at-risk and 47%, USPSTF-at-risk) and over half had not had cholesterol screening within the 
previous 5 years. Pharmacologic and lifestyle interventions for dyslipidemia are available 
for reproductive age women, and this age group frequently interacts with the health care 
system for their reproductive health care needs. Therefore, reproductive health visits may be 
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perfect opportunities to educate, screen, and treat or refer younger women with 
dyslipidemia. Younger women may perceive their risk of dyslipidemia to be low, and, 
therefore not realize the importance of heart-healthy lifestyles. As well, medical providers 
may consider cholesterol screening a low priority during reproductive care visits.
NCEP ATP III, which is supported by AHA, recommends universal screening for women 
≥20 years.7,8 However, the USPSTF’s most recent review of the literature found insufficient 
evidence of net benefit for lipid screening in all young adults and women 45 years or older 
not at increased risk for coronary heart disease. Given that unhealthy diet, abdominal 
obesity, and physical inactivity were the most prevalent AHA risk factors among younger 
and older women alike, and therapeutic lifestyle changes are indicated more often than is 
drug therapy for management of dyslipidemia in young women, our results indicate that a 
large proportion of women of reproductive age would benefit from lifestyle counseling.
While this study provides prevalence estimates of dyslipidemia based on USPSTF and AHA 
definitions of risk, what it does not address is the number of CVD events that would be 
averted if these cases of dyslipidemia were diagnosed and treated. The practical costs of 
screening and the risk-to-benefit ratio of statin therapy for these additional women need to 
be estimated and considered. Future research is needed to assess whether identification and 
treatment of all women with dyslipidemia will decrease CVD mortality among them later in 
life.
The findings in this report are subject to limitations. First, measurement error is possible. 
Self-reported data are subject to recall bias, particularly time since last screening, 24-hour 
diet recall, and physical activity. Specifically, respondents tend to underestimate time since 
last screening and may self-report screening occurred more recently than it actually did.20,21 
Survey respondents also tend to overestimate physical activity and under report food 
intake.22–24 In one study, less than 10% of adults met the recommended level of physical 
activity when objectively measured using accelerometers, but 62% achieved recommended 
physical activity levels when assessed by self-report.22 Conversely, the mean percentage of 
energy intake underreporting in studies that use the 24 hour recall assessment method ranges 
from 22%–67% (median 31%).23 Furthermore, the approach used to estimate usual dietary 
intake may lead to misclassification. Unhealthy diet was conservatively estimated by using 
most of the available measures included in the AHA recommendations for a healthy diet, but 
key recommended nutrients (fruits, vegetables, and nuts) were unavailable. Nonetheless, 
nearly all women met the criteria for having an unhealthy diet. Second, bias from 
misclassification is possible. While the NCEP ATP III suggests that non-HDL-C may be 
preferred over LDL-C for clinical purposes of evaluating risk, non-HDL-C may be a less 
reliable predictor of risk than LDL-C in individuals with high triglyceride levels.8 As a 
sensitivity analysis, we estimated prevalence of high LDL-C on the fasting subsample and 
results were not statistically different from our reported prevalence of high non-HDL-C. 
Because the NHANES asks about family history of heart attack before age 50—which is 
broader than the USPSTF definition (<50 for male relatives and <60 for female relatives) or 
the AHA definition (<55 in men and <65 in women)—misclassification may overestimate 
prevalence estimates of the two at-risk groups. Additionally, CVD prevalence may be 
overestimated as some women with congenital heart disease or other heart conditions 
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unrelated to atherosclerosis may be misclassified. This may have inflated overall reported 
CVD prevalence, estimates that use CVD as basis for determining risk, including variables 
for Framingham 10-year CHD risk, USPSTF and AHA risk categories, and prevalence of 
high non-HDL-C. However, we believe this would be rare. Conversely, the percent of AHA-
at-risk women may be underestimated since NHANES does not collect information on other 
important CVD risk factors such as gestational hypertension or lupus.
Conclusion
Given half of reproductive age women and nearly three-fourths of older women in this 
sample were USPSTF-at-risk but nearly all women were AHA-at-risk, education is needed 
to inform the public and professionals about CVD risk in women.25 In order for medical 
providers to appropriately identify, diagnose, monitor, and treat at-risk women, consensus is 
needed about what at-risk means. The USPSTF definition of at-risk identified a similar 
percentage of women with dyslipidemia as the AHA definition, but the difference in 
absolute numbers is noteworthy. Given a high prevalence of AHA risk factors and 
dyslipidemia among young women, future research is needed to assess whether 
identification and treatment of young women with dyslipidemia will decrease CVD 
mortality among them later in life.
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Table 1
Source of Data on Cardiovascular Disease Risk Factor According to U.S. Preventive Services Task Force and 
American Heart Association, National Health and Nutrition Examination Survey, 2007–2008
Risk factors USPSTF10 AHA7 NHANES measure
CVD or equivalenta,b Self-reported:
X X     Congestive heart failure
X X     Coronary heart disease
X X     Angina, also called angina pectoris
X X     Heart attack (also called myocardial infarction)
X     Stroke
X     Weak or failing kidneys
X End-stage or chronic kidney disease defined by albumin to creatinine ratio and 
glomerular filtration rate
X Diabetes
Diabetes X X Self-reported medical diagnosis of diabetes or sugar diabetes
X X A1c test ≥6.5%
Hypertension X X Prescribed medicine for hypertension
X X Mean SBP ≥140mm Hg (≥2 measurements)
X X Mean DBP ≥90mm Hg (≥2 measurements)
Pre-hypertension X Mean SBP 120–139mm Hg (≥2 measurements)
X Mean DBP 80–89mm Hg (≥2 measurements)
Tobacco Use X X Self-reported current cigarette smoking and ≥100 cigarettes smoked in lifetime
Obesity X X Calculated BMI from body measurements
X Central adiposity (waist circumference)
Family history of premature 
CVDc,d
X X Blood relative ever medically diagnosed with a heart attack or angina before the age 
of 50
Poor diet X Non-accordance with DASH-like diet
Physical inactivity X Self-reported time spent doing moderate- or vigorous-intensity activity as part of 
work, sports, fitness, or recreational activities
Rheumatoid arthritis X Self-reported medical diagnosis of rheumatoid arthritis
Gestational diabetes X Self-reported medical diagnosis of gestational diabetes
10-year predicted CVD 
Framingham risk ≥10%
X Framingham Point Scores based on age, total cholesterol, HDL-C, smoking status, 
and blood pressure treatment and control
a
U.S. Preventive Services Task Force (USPSTF) defines as personal previous history of coronary heart disease (CHD) or non-coronary 
atherosclerosis (e.g., peripheral arterial disease, abdominal aortic aneurism, or carotid artery stenosis).
b
American Heart Association (AHA) defines as clinically manifest CHD, cerebrovascular disease or peripheral arterial disease, abdominal aortic 
aneurism, or end-stage or chronic kidney disease.
c
USPSTF defines as cardiovascular disease (CVD) diagnosis in a close biological relative before age 50 for male relatives (father/brother) or age 
60 in female relatives (mother/sister).
d
AHA defines as premature CVD occurring in first-degree relatives in men <55 years or in women <65 years.
BMI, body mass index; DASH, Dietary Approaches to Stop Hypertension; DBP, diastolic blood pressure; HDL-C, high-density lipoprotein 
cholesterol; SBP, systolic blood pressure; NHANES, National Health and Nutrition Examination Survey.
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Table 2
Recommended Dash15 and AHA7 Targets for Healthy Diet
Component Target
DASH
   Fiber ≥ 31g/2,100 kcal per daya
   Saturated fat ≤6% energy per day
   Protein ≥ 18% of energy per day
   Sodium ≤ 2.4 g/2,100 kcal per dayb
AHA
   Fish ≥ 2 3.5-ounce servings per week
   Alcohol ≤ 1 serving per dayc
a
Accordance with target defined as ≥14.8 g/1,000 kcal.
b
Accordance with target defined as ≤1,143mg/1,000kcal based on the Seventh Report of the Joint National Committee on Prevention, Detection, 
Evaluation, and Treatment of High Blood Pressure recom-mendation.26
c
Equivalent of one serving (www.cdc.gov/alcohol/faqs.htm).
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Table 3
Sample Characteristics for Women Aged 20 or More Years, Based on National Health and Nutrition 
Examination Survey, 2007–2008*
Variables
20–44 years percent (SD)
(n=911, 51.2%)






    Mexican American 11.5 (0.8) 6.0 (0.6) 9.1 (0.5)
    White, non-Hispanic 63.0 (1.7) 74.5 (1.6) 68.0 (1.2)
    Black, non-Hispanic 13.0 (1.0) 10.7 (0.9) 12.0 (0.7)
    Other race/multi-racial 12.6 (1.2) 8.8 (1.1) 10.9 (0.8)
  Annual family income
    $0-$24,999 23.4 (1.5) 26.7 (1.7) 24.8 (1.1)
    $25,000-$44,999 19.7 (1.5) 19.7 (1.7) 19.7 (1.1)
    $45,000-$74,999 25.0 (1.8) 18.5 (1.9) 22.1 (1.3)
    ≥ $75,000 27.9 (1.9) 28.1 (2.2) 28.0 (1.5)
    Unknown 4.1 (0.7) 7.0 (1.1) 5.4 (0.6)
  Education (highest level)
    Less than 12th grade 17.8 (1.3) 22.5 (1.6) 19.9 (1.0)
    12th grade, GED, or high school graduate 20.2 (1.5) 26.1 (2.0) 22.8 (1.2)
    Some college or associates degree 36.3 (2.0) 26.7 (2.0) 32.1 (1.4)
    College graduate or above 25.7 (1.9) 24.8 (2.1) 25.3 (1.4)
Health care access indicators
  Health insurancea
    Underinsured or uninsuredb 24.8 (1.6) 12.7 (1.3) 19.5 (1.1)
    Publicc 14.7 (1.3) 19.3 (1.5) 16.7 (1.0)
    Private 60.5 (1.9) 68.0 (1.9) 63.8 (1.3)
  Time since last visit with a health care provide†
    12 months or less 87.7 (1.3) 91.4 (1.3) 89.3 (0.9)
    >1 year and <3 years 8.7 (1.1) 6.0 (1.2) 7.5 (0.8)
    More than 3 years or never 3.7 (0.7) 2.6 (0.5) 3.2 (0.5)
  Cholesterol checked within past 5 years
    No 51.4 (2.1) 21.1 (1.8) 37.9 (1.5)
    Yes 48.6 (2.1) 78.9 (1.8) 62.1 (1.5)
Cardiovascular disease (CVD) risk factors
  CVDd
    No 99.2 (0.3) 93.9 (0.8) 96.9 (0.4)
    Yes 0.8 (0.8) 6.1 (0.8) 3.1 (0.4)
  Diabetes
    No 90.2 (1.1) 57.2 (2.1) 75.6 (1.2)
    Pre-diabetes 7.6 (1.0) 29.1 (1.9) 17.1 (1.0)
    Yes 2.3 (0.5) 13.7 (1.3) 7.3 (0.6)
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Variables
20–44 years percent (SD)
(n=911, 51.2%)




  Blood pressure status
    Normal 75.8 (1.7) 31.7(2.2) 56.3 (1.5)
    Pre-hypertensione 16.7 (1.5) 25.4 (2.0) 20.6 (1.2)
    Hypertensionf 7.5 (1.0) 43.0 (2.2) 23.3 (1.2)
  High blood cholesterolg
    No 60.5 (2.0) 36.6 (2.2) 50.0 (1.5)
    Yes 39.5 (2.0) 63.5 (2.2) 50.0 (1.5)
  Current tobacco use†
    No 77.0 (1.7) 81.6 (1.7) 79.0 (1.2)
    Yes 23.0 (1.7) 18.4 (1.7) 21.0 (1.2)
  Obesityh,†
    No 66.2 (1.9) 65.4 (2.1) 65.9 (1.4)
    Yes 33.8 (1.9) 34.6 (2.1) 34.2 (1.4)
  Abdominal obesityi
    No 46.2 (2.0) 34.5 (2.3) 58.9 (1.5)
    Yes 53.8 (2.0) 65.5 (2.3) 41.1 (1.5)
  Family history of CVDj
    No 88.3 (1.3) 83.3 (1.6) 86.1 (1.0)
    Yes 11.7 (1.3) 16.7 (1.6) 13.9 (1.0)
  Unhealthy diet
    No 6.8 (1.0) 12.4 (1.5) 9.2 (0.9)
    Yes 93.2 (1.0) 87.6 (1.5) 90.8 (0.9)
  Physical activityk
    Inactive 42.5 (1.9) 58.2 (2.3) 49.4 (1.5)
    Insufficiently active 20.5 (1.7) 16.4 (1.7) 18.7 (1.2)
    Physically active 37.0 (2.0) 25.4 (2.1) 31.9 (1.5)
  Rheumatoid arthritis
    No 98.2 (0.5) 93.3 (0.9) 96.0 (0.5)
    Yes 1.8 (0.5) 6.7 (0.9) 4.0 (0.5)
  Gestational diabetes†
    No 93.8 (1.0) 96.2 (0.9) 94.9 (0.7)
    Yes 6.2 (1.0) 3.8 (0.9) 5.2 (0.7)
  10-year CHD riskl
    <10% 99.1 (0.3) 80.5 (1.5) 90.9 (0.7)
    10–20% 0.2 (0.1) 10.4 (1.2) 4.6 (0.5)
    >20% 0.8 (0.3) 9.1 (1.0) 4.5 (0.5)
  At risk according to USPSTF guidelinesm
    No 45.0 (2.0) 25.8 (2.1) 36.6 (1.5)
    Yes 55.0 (2.0) 74.2 (2.1) 63.4 (1.5)
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Variables
20–44 years percent (SD)
(n=911, 51.2%)




  At risk according to AHA guidelinesn,†
  No 0.5 (0.2) 0.4 (0.4) 0.5 (0.2)
  Yes 99.5 (0.2) 99.6 (0.4) 99.5 (0.2)
*
Weighted percentages (standard errors) presented; weighted n = 69,597,631. Percent totals may not sum to 100% due to rounding; chi-square 
<0.05 except as noted.
†
Differences between groups are not statistically significant; p<0.05.
a
Persons with more than one type of insurance were assigned to the first appropriate category in the hierarchy of coverage comprehensiveness.
b
Includes persons with no coverage, and private single service plans.
c
Includes Medicaid, MediGap, Medicare, SCHIP, IHS coverage, military insurance, and state-sponsored or other governmental insurance plans.
d
Includes coronary heart disease, angina pectoris, myocardial infarction, stroke, and other heart disease.
e
Defined as mean systolic blood pressure 120–139 mm Hg or diastolic blood pressure 80–89 mm Hg based on two or more measures.
f
Defined as mean systolic blood pressure ≥ 140 mm Hg or diastolic blood pressure ≥ 90 mm Hg based on two or more measures.
g
Defined as high TC (≥ 200 mg/dL), low HDL-C (<40mg/dL), or high non-HDL according to thresholds for risk levels in ATP III plus 30 mg/dL; 
high non-HDL-C defined as ≥ 130 mg/dL if CHD or CHD equivalent, ≥ 160 mg/dL if two or more risk factors and Framingham 10-year risk < 
20%, and ≥ 190 mg/dL if 0–1 risk factors.
h
Defined as ≥30 weight (kg) / [height (m)]2.
i
Defined as waist circumference > 88 centimeters.
j
Having a living or deceased close biological relative who was told they had a heart attack or angina before age 50 years.
k
Inactive: 0 minutes/week; insufficiently active: <149 minutes/week; active: 150+ minutes/week.
l
Framingham point scores and 10-year risk estimates are available at: www.nhlbi.nih.gov/guidelines/cholesterol; CVD or CVD equivalent 
considered >20%.
m
As defined by the United States Preventive Services Task Force;10 includes diabetes, personal or premature family history of CVD, tobacco use, 
hypertension, and obesity.
n
Defined by the American Heart Association;7 includes personal or premature family history of CVD, stroke, diabetes, 10-year predicted CVD risk 
≥ 10%, cigarette smoking, pre-hypertension, hypertension, hypertension treatment, dyslipidemia, dyslipidemia treatment, obesity/ central adiposity, 
poor diet, physical inactivity, rheumatoid arthritis, and history of gestational diabetes.
IHS, Indian Health Service; SCHIP, State Children’s Health Insurance Program.
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